Embecta vs Inspire Medical Systems
Embecta reported revenue of $1.1 billion in fiscal 2025, 1.2 times Inspire Medical Systems' $912 million in fiscal 2025. Embecta's revenue fell 3.8% in its latest year, and Inspire Medical Systems' grew 13.6%. Embecta had an operating margin of 22.4%, against 5.6% at Inspire Medical Systems. Free cash flow was $182 million at Embecta and $78 million at Inspire Medical Systems. Their fiscal years end in different months (September 30 and December 31), so the periods don't line up exactly.
Side by side
| Embecta | Inspire Medical Systems | |
|---|---|---|
| Latest fiscal year | FY2025, Sep 30, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $1.1B | $912M |
| Revenue growth | −3.8% | 13.6% |
| Revenue growth a year, last 5 years | −0.1% | 51.2% |
| Gross margin | 62.6% | 85.4% |
| Operating margin | 22.4% | 5.6% |
| Net margin | 8.8% | 15.9% |
| Free cash flow | $182M | $78M |
| Free cash flow margin | 16.9% | 8.6% |
| Return on capital | 29.3% | 14.2% |
| Net debt to EBITDA | 4.3x | −4.8x |
| Dividends and buybacks | $35M | $175M |
| Change in diluted share count | 1.0% | −2.6% |
| Last close | $6.19 | $56.28 |
| P/E at the last close | 4.2× | 16.8× |
| Insider trades, last 12 months | bought $557,850, sold $37,003 | sold $665,952 |
| Piotroski F-score | 6 of 9 | 5 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
EmbectaInspire Medical Systems
Operating margin
Percent of revenue
EmbectaInspire Medical Systems
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
EmbectaInspire Medical Systems
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Embecta and Inspire Medical Systems pages.